Naperville, IL -- (ReleaseWire) -- 02/13/2014 -- Reportstack, provider of premium market research reports announces the addition of Allergy Therapeutics plc - Product Pipeline Review - 2014 market report to its offering
Allergy Therapeutics plc - Product Pipeline Review - 2014
Global Market Directs pharmaceuticals report, Allergy Therapeutics plc - Product Pipeline Review - 2014 provides data on the Allergy Therapeutics plcs research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from proprietary databases, Allergy Therapeutics plcs corporate website, SEC filings, investor presentations and featured press releases, both from Allergy Therapeutics plc and industry-specific third party sources, put together by team.
- Allergy Therapeutics plc - Brief Allergy Therapeutics plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Allergy Therapeutics plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Allergy Therapeutics plc with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Allergy Therapeutics plcs pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Allergy Therapeutics plcs strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Allergy Therapeutics plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Allergy Therapeutics plcs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Allergy Therapeutics plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Allergy Therapeutics plc and identify potential opportunities in those areas.
To view the table of contents for this market research report please visit